

Ref: 47/SE/LC/2025-26

Date: September 29, 2025

Scrip Code BSE: 544122
NSE: ENTERO
ISIN: INE010601016

To,
**Head, Listing Compliance Department
BSE Limited**
Phiroze Jeejeebhoy Towers Dalal Street,
Mumbai - 400 001.

**Head, Listing Compliance Department
National Stock Exchange of India Limited**
Exchange Plaza, Plot No. C/1. G Block,
Bandra -Kurla Complex, Bandra (East),
Mumbai- 400051

Dear Sir/Madam,

Subject: Outcome of Board Meeting held on September 29, 2025.

Reference: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. ("SEBI Listing Regulations")

Pursuant to Regulation 30 of the SEBI Listing Regulations, we wish to inform you that the Board of Directors of the Company, at its meeting held today, inter alia, considered and approved of the following:

1. sale of entire stake (100%) in Suprabhat Pharmaceutical Private Limited ("**Suprabhat**"), a wholly owned subsidiary of the Company.
2. The Board has approved, inter-alia, to execute Share Purchase Agreement ('SPA'), for acquiring 60% stake in Ace Cardiopathy Solutions Private Limited ("**Ace Cardiopathy**"), Target Company, subject to satisfactory completion of due diligence and execution of the definitive agreements.

The details required to be furnished in compliance with Regulation 30 read with Part A of Schedule III of SEBI Listing Regulations and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024, as amended, are enclosed as **Annexure-A and Annexure B** respectively.

The Board Meeting commenced at 11:30 AM (IST) and concluded at 01:20 PM (IST).

This outcome will also be uploaded on the website of the Company.

You are requested to take the same on record.

Yours faithfully,
For **Entero Healthcare Solutions Limited**

Sanu Kapoor
**Vice President- General Counsel, Company Secretary
& Compliance Officer**

Encl: as above

Annexure-A

Details in terms of Regulation 30 read with Para A of Part A of Schedule III of SEBI Listing Regulations and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024:

Sr No.	Particulars	Details									
1	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year	Income and Networth of Suprabhat Pharmaceutical Private Limited: <table border="1"> <thead> <tr> <th>Particulars</th><th>Amount (INR in millions)</th><th>Percentage (%)</th></tr> </thead> <tbody> <tr> <td>Income</td><td>198.76</td><td>0.39</td></tr> <tr> <td>Networth</td><td>2.38</td><td>0.01</td></tr> </tbody> </table> <i>Note: As per the audited financial statements as on March 31, 2025.</i> <i>Note: percentage reflects Suprabhat's contribution to Entero's Consolidated Income/net worth</i>	Particulars	Amount (INR in millions)	Percentage (%)	Income	198.76	0.39	Networth	2.38	0.01
Particulars	Amount (INR in millions)	Percentage (%)									
Income	198.76	0.39									
Networth	2.38	0.01									
2	Date on which the agreement for sale has been entered into	September 29, 2025									
3	The expected date of completion of sale/disposal	During the Financial Year 2025-26									
4	Consideration received from such sale/disposal	upto INR 37,00,000/-									
5	Brief details of buyers and whether any of the buyers belong to the promoter/promoter group/group companies. If yes, details thereof	Name of the Buyers (erstwhile Promoters): - Mr. Yash Sudhir Biradar - Ms. Kavita Sudhir Biradar The Buyers do not belong to the promoter, promoter group of the Company. However, they were erstwhile promoters of Suprabhat.									
6	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length	Yes, the said transaction would be considered as Related Party Transaction and shall be on an Arm's Length basis.									
7	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations	Not Applicable									
8	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	Not Applicable									

Annexure-B

Details in terms of Regulation 30 read with Para A of Part A of Schedule III of SEBI Listing Regulations and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024:

Sr. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	M/s. Ace Cardiopathy Solutions Private Limited, a company incorporated in Delhi, India, bearing CIN U51909DL2009PTC196486 (“Ace Cardiopathy”/ “Target Company”). Ace Cardiopathy is inter -alia engaged in the business of Wholesale of distribution of medical devices and other healthcare and allied products. Paid-up equity share capital of Ace Cardiopathy is INR. 29,80,660/- (Indian Rupees Twenty-Nine Lakhs Eighty Thousand Six Hundred and sixty only) consisting of 2,98,066 equity shares having face value of INR 10/- each (Ten Only) The turnover of Ace Cardiopathy is mentioned in Annexure 1
2	whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm s length”	No, the acquisition shall not fall within related party transaction and promoter/promoter group/ group companies do not have any interest in the Ace Cardiopathy.
3	Industry to which the entity being acquired belongs	Ace Cardiopathy operates in same industry i.e. Wholesale distribution of medical devices and other healthcare and allied products.
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The business of Ace Cardiopathy is in line with the business of the Company i.e. wholesale distribution of medical devices and other allied products.
5	brief details of any governmental or regulatory approvals required for the acquisition;	Not applicable.
6	indicative time period for completion of the acquisition;	The acquisition shall be completed by January 31, 2026.
7	consideration whether cash consideration or share swap or any other form and details of the same	The acquisition of Ace Cardiopathy will be through cash consideration.
8	cost of acquisition and/ or the price at which the shares are acquired;	The cost of acquisition shall range between INR 59.30 Crore to INR 77.10 Crore for acquiring 60% (sixty percent) stake in the target company subject to adjustments for net debt, normalized working capital and achievement of certain conditions.
9	percentage of shareholding / control acquired and / or number of shares acquired;	60% of Shareholding

10	brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Ace Cardiopathy is inter-alia engaged in the business of wholesale distribution of medical devices and other allied products. Ace Cardiopathy was incorporated on December 01, 2009. Ace Cardiopathy conducts its business only in India. The turnover of Ace Cardiopathy is mentioned in Annexure 1.
----	---	---

Annexure 1

Details of revenue are mentioned below:

<i>(Figures in Rs. Mn.)</i>			
Name of the Company	F.Y - 2024-2025 (Unaudited)	F.Y - 2023-2024 (Audited)	F.Y - 2022-2023 (Audited)
Ace Cardiopathy	1548	1762	1530